<br />
NEUROLOGY<br />
Charcot supplement • emjreviews.com<br />
INSIDE<br />
Predictive Value of MRI<br />
for Clinical Outcomes<br />
PREDICTIVE VALUE OF MRI FOR CLINICAL OUTCOMES<br />
Summary of presentations from the Genzyme-supported satellite<br />
symposium, held at the 22nd Annual Meeting of the European<br />
Charcot Foundation, Baveno, Italy, on 20th-22nd November 2014<br />
Chairperson<br />
Massimo Filippi1<br />
Speakers<br />
Maria Pia Sormani,2 Andrew Chan,3 Hans-Peter Hartung4<br />
1. Vita-Salute San Raffaele University, Milan, Italy<br />
2. University of Genoa, Genoa, Italy<br />
3. Ruhr University Bochum, Bochum, Germany<br />
4. University of Düsseldorf, Düsseldorf, Germany<br />
Disclosure: Professor Massimo Filippi serves on the scientific advisory boards for Teva and Biogen<br />
Idec; has received compensation for consulting services and/or speaking activities from Bayer Schering<br />
Pharma, Biogen Idec, Merck Serono, San<a title="EMJ Neurol. 2015 Suppl 2 page 1" href="http://viewer.zmags.com/publication/b9f996ee?page=1"> NEUROLOGY Charcot supplement • emjreviews.com </a>
<a title="EMJ Neurol. 2015 Suppl 2 page 2" href="http://viewer.zmags.com/publication/b9f996ee?page=2"> PREDICTIVE VALUE OF MRI FOR CLINICAL OUTCOMES Sum</a>
<a title="EMJ Neurol. 2015 Suppl 2 page 3" href="http://viewer.zmags.com/publication/b9f996ee?page=3"> For a surrogate marker to be valid, it mu</a>
<a title="EMJ Neurol. 2015 Suppl 2 page 4" href="http://viewer.zmags.com/publication/b9f996ee?page=4"> cytokine production, and modulating t</a>
<a title="EMJ Neurol. 2015 Suppl 2 page 5" href="http://viewer.zmags.com/publication/b9f996ee?page=5"> Treatment-naïve </a>
<a title="EMJ Neurol. 2015 Suppl 2 page 6" href="http://viewer.zmags.com/publication/b9f996ee?page=6"> T2 lesions) in the Phase III trials </a>
<a title="EMJ Neurol. 2015 Suppl 2 page 7" href="http://viewer.zmags.com/publication/b9f996ee?page=7"> 19. Coles AJ et al; CARE-MS II investigators. Ale</a>